530
Views
7
CrossRef citations to date
0
Altmetric
Articles

Oral antifungal therapies for toenail onychomycosis: a systematic review with network meta-analysis toenail mycosis: network meta-analysis

, , , &
Pages 121-130 | Received 19 Jan 2020, Accepted 08 Feb 2020, Published online: 20 Feb 2020
 

Abstract

Aim

Toenail fungal infections account for half of all nail disease cases, and a highly negative impact on patient quality of life. Our aim was to compare the efficacy and safety of commercially available oral antifungals for onychomycosis.

Methods

A systematic review was performed in PubMed and Scopus. Randomized controlled trials evaluating the effect of oral antifungals on mycological cure, discontinuation and adverse events were included. Network meta-analyses were built for each outcome. Results were reported as odds ratios (OR) with 95% credibility intervals (CrI). Ranking probabilities were calculated by surface under the cumulative ranking analysis (SUCRA).

Results

We included 40 trials (n = 9568). Albaconazole 400 mg (OR 0.02 [95% CrI 0.01–0.07] versus placebo), followed by posaconazole 200–400 mg and terbinafine 250–350 mg were considered the best therapies (SUCRA probabilities over 75%). For the networks of discontinuation and individual adverse events, few significant differences among treatments were observed, but itraconazole 400 mg was considered the safest drug (SUCRA around 25%). Albaconazole 400 mg, posaconazole 200–400 mg, and terbinafine 250–350 mg were the most effective therapies for onychomycosis, while itraconazole 400 mg was the safest.

Conclusion

The profile of albaconazole and posaconazole compared to current first-line therapies should be further investigated in well-designed trials.

Acknowledgments

The authors gratefully acknowledge the Postgraduate Program in Pharmaceutical Sciences, Federal University of Parana, for allowing us to perform this study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.